Plegridy(peginterferon beta-1a)
Plegridy (peginterferon beta-1a) is a protein pharmaceutical. Peginterferon beta-1a was first approved as Plegridy on 2014-07-18. It is used to treat multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Plegridy
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Peginterferon beta-1a
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Plegridy | peginterferon beta-1a | Biogen | N-125499 RX | 2014-08-15 | 6 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| plegridy | Biologic Licensing Application | 2021-01-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple sclerosis | EFO_0003885 | D009103 | G35 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 6 | 4 | 1 | 11 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 2 | — | — | 1 | 4 | 7 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 5 | — | — | — | — | 5 | ||
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PEGINTERFERON BETA-1A |
| INN | peginterferon beta-1a |
| Description | Peginterferon beta-1a', sold under the brand name Plegridy, is medication used to treat multiple sclerosis.
|
| Classification | Protein |
| Drug class | PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1211327-92-2 |
| RxCUI | 1546168 |
| ChEMBL ID | CHEMBL2108677 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09122 |
| UNII ID | I8309403R0 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Plegridy - Biogen
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 243 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,597 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more